- ►diabetesjournals.org M Clemenz, N Frost, M Schupp, S Caron, A Foryst- … - Diabetes, 2008 - Am Diabetes Assoc RESULTS—Telmisartan significantly induced the PPARα target genes carnitine palmitoyl transferase
1A (CPT1A) in human HepG2 cells and acyl-CoA synthetase long-chain family member 1
(ACSL1) in murine AML12 cells in the micromolar range. Telmisartan-induced CPT1A ... Cited by 6 - Related articles - BL Direct - All 3 versions
D Walcher, K Hess, P Heinz, K Petscher, D Vasic, U … - Hypertension, 2008 - Am Heart Assoc Migration of CD4-positive lymphocytes into the vessel wall represents an important step in early
atherogenesis. Telmisartan is an angiotensin type 1 receptor (AT1R) blocker with peroxisome
proliferator-activated receptor (PPAR)- –activating properties. The present study ... Cited by 5 - Related articles - All 6 versions
EF Georgescu - Advances in Therapy, 2008 - Springer Nonalcoholic fatty liver disease (NAFLD) is a condition pathogenically linked to metabolic syndrome
(MS) by insulin resistance (IR), and charac- terized by hepatic steatosis in the absence of significant
alcohol use, hepato- toxicity, and/or other known liver diseases. The principles of NAFLD ... Cited by 1 - Related articles - All 2 versions
Y Takeshita, T Takamura, H Ando, E Hamaguchi, A … - European Journal of …, 2007 - Elsevier Tumor necrosis factor (TNF)-α and local activation of the renin–angiotensin system may contribute
to insulin resistance and atherosclerosis. In this study, we investigated the involvement of these
mediators in the liver. We found that the gene expression of renin–angiotensin system ... Cited by 7 - Related articles - All 3 versions
- ►diabetesjournals.org [PDF] M Clemenz, N Frost, M Schupp, S Caron, A Foryst- … - Diabetes, 2008 - Am Diabetes Assoc Page 1. Liver-Specific PPARα-Target Gene Regulation by the Angiotensin Type 1 Receptor
Blocker Telmisartan Markus Clemenz* 1 , Nikolaj Frost* 1 , Michael Schupp 2 , Sandrine Caron
3 , Anna Foryst-Ludwig 1 , Christian Böhm 1 , Martin Hartge 1 , Ronald Gust 4 , ... Cited by 2 - Related articles - All 2 versions
K Fujita, M Yoneda, K Wada, H Mawatari, H … - Digestive diseases and …, 2007 - Springer Dig Dis Sci (2007) 52:3455–3464 DOI 10.1007/s10620-007-9741-4 ... Telmisartan, An Angiotensin
II Type 1 Receptor Blocker, Controls ... Koji Fujita · Masato Yoneda · Koichiro Wada · Hironori
Mawatari · Hirokazu Takahashi · Hiroyuki Kirikoshi · Masahiko Inamori · Yuichi Nozaki · ... Cited by 21 - Related articles - BL Direct - All 4 versions
S Yamada, N Ano, K Toda, A Kitaoka, K Shiono, G … - Hypertension …, 2008 - nature.com To examine the effects of telmisartan on peroxisome proliferator–activated receptor
activation, we compared the effects of telmisartan with those of candesartan on adipocytokines
and glucose and lipid metabolism in vivo and in vitro. In vivo, 56 patients with both type 2 ... Cited by 5 - Related articles - All 2 versions
T Yoshida, S Yamagishi, T Matsui, K … - The Journal of …, 2008 - ingentaconnect.com This study examined whether telmisartan, a unique angiotensin II type 1 receptor blocker
(ARB) with peroxisome proliferator-activated receptor-γ (PPAR-γ)-modulating activity, improved
insulin resistance in advanced glycation end-product (AGE)-exposed human hepatoma ( ... Cited by 5 - Related articles - BL Direct - All 3 versions
[CITATION] The clinical aspects of non-alcoholic fatty liver disease
T Inoue, T Morooka, K Moroe, H Ikeda, K Node - Hormone and metabolic …, 2007 - cat.inist.fr Saga Telmisartan Aggressive Research(STAR) is a single-arm, prospective multi-center trial
to evaluate the effectiveness of treatment with telmisartan in patients with hypertension. A total
of 197 patients with a systolic blood pressure of> 140 or a diastolic blood pressure of ≥ ... Cited by 11 - Related articles - BL Direct - All 4 versions
